Aggressive lymphoma in the elderly.

Abstract

Persons 65 years of age and older are the fastest growing segment of the United States population. Over the next 30 years they will comprise approximately 20% of the population. There will be a parallel rise in the number of patients with non-Hodgkin's lymphoma. Age has long been known to be an adverse prognostic factor. Clinical trials of older patients are complicated by the effect of comorbid illness, particularly its effect on overall survival. CHOP (cyclophosphamide, Adriamycin, vincristine, prednisone) remains the standard therapy for all patients with aggressive non-Hodgkin's lymphoma. There are a number of regimens which may be beneficial for older patients with significant comorbidity and poor performance status. The randomized trials in the elderly has reaffirmed CHOP and emphasize the need for adequate dosing, maintaining schedule and anthracyclines. Relapsed patients have a poor prognosis but selected fit older patients may benefit from aggressive reinduction regimens and possibly bone marrow transplantation. Future research should include defining the role of comorbidity, measurement of organ dysfunction and assessment of performance status with geriatric functional scales. New drug treatments should also be explored.

• Authors: S M Lichtman
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 33 Issue 2 Pg. 119-28 (Feb 2000) ISSN: 1040-8428 [Print] Netherlands
• PMID: 10737373 (Publication Type: Journal Article, Review)

Topics

• Age Factors
• Aged
• Aged, 80 and over
• Humans
• Lymphoma (pathology, physiopathology, therapy)